Fulgent Genetics Inc

For the period ended Jun 30, 2024. Filed Aug 2, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 2, 2024

FLGT$26.15+10.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

(in thousands, except per share data)

	Three Months Ended June 30,		Six Months Ended June 30,
	2024	2023	2024	2023
Revenue	$71,028	$67,853	$135,513	$134,021
Cost of revenue	44,537	47,281	86,918	94,638
Gross profit	26,491	20,572	48,595	39,383
Operating expenses:
Research and development	13,486	9,692	24,920	19,474
Selling and marketing	8,595	10,723	17,584	20,806
General and administrative	21,326	17,993	42,815	39,795
Amortization of intangible assets	1,990	1,962	3,980	3,930
Total operating expenses	45,397	40,370	89,299	84,005
Operating loss	(18,906)	(19,798)	(40,704)	(44,622)
Interest and other income, net	7,692	5,098	15,317	8,873
Loss before income taxes	(11,214)	(14,700)	(25,387)	(35,749)
Benefit from income taxes	(2,124)	(3,110)	(2,451)	(8,310)
Net loss from consolidated operations	(9,090)	(11,590)	(22,936)	(27,439)
Net loss attributable to noncontrolling interests	380	361	764	870
Net loss attributable to Fulgent	$(8,710)	$(11,229)	$(22,172)	$(26,569)
Net loss per common share attributable to Fulgent
Basic	$(0.29)	$(0.38)	$(0.74)	$(0.90)
Diluted	$(0.29)	$(0.38)	$(0.74)	$(0.90)
Weighted-average common shares:
Basic	30,098	29,813	29,933	29,675
Diluted	30,098	29,813	29,933	29,675

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.